The study results show that UAZ or U, A, and Z given orally to diabetic mice displayed hypoglycemic and hypo-lipidemic effects by reducing liver weight and ameliorating the activities of hepatic enzymes such as fructose-1,6-bisphosphatase hexokinase, glucose-6-phosphatase, phosphofructokinase, alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) compared to the T2DM group. This evidence concerns the gene G6PC1 and type 2 diabetes mellitus.